Citius Oncology CTOR
NASDAQ CTOR
$0.76 +0.01 (+0.98%)
At close: Aug 20, 2026 · 2:44 PM UTC

Citius Oncology (CTOR) Receivables (2025 - 2026)

Citius Oncology (CTOR) posted quarterly Receivables of $1.1 million for Q1 2026, down 73.35% quarter-over-quarter from $4.0 million in Q4 2025.

Citius Oncology (CTOR) Receivables (2025 - 2026) Analysis & Trends

Citius Oncology (CTOR) has reported Receivables for 2 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Haleon 43.98 Bn 43.02 Bn - 3.07 Bn
2 Teva Pharmaceutical Industries 43.07 Bn 39.42 Bn 2.15 Bn 3.49 Bn
3 Zoetis 31.53 Bn 29.85 Bn 1.05 Bn 1.57 Bn
4 Takeda Pharmaceutical 28.60 Bn 22.80 Bn 5.10 Bn 5.84 Bn
5 United Therapeutics 22.13 Bn 19.47 Bn 683.80 Mn 310.30 Mn
6 Viatris 18.75 Bn 17.86 Bn 1.46 Bn 3.67 Bn
7 Neurocrine Biosciences 15.53 Bn 15.14 Bn 935.80 Mn 887.00 Mn
8 Elanco Animal Health 11.69 Bn 11.16 Bn 798.00 Mn 1.15 Bn
9 Dr Reddys Laboratories 10.13 Bn 9.97 Bn - 1.08 Bn
10 Citius Oncology 81.99 Mn 81.99 Mn 1.00 Mn 686,235.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1.08 Mn
Dec 31, 2025 4.05 Mn